ClinicalTrials.gg
RecruitingNCT06732128VRNUpdated Dec 13, 2024

Nature-based Virtual Reality Intervention for Depression in Alzheimer's Disease

An interventional study of nature-based virtual reality applications and videos and nature-based videos in Alzheimer Disease and Depression, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 321 studies in Alzheimer Disease with a site in Canada — 60 open to participants now, 81 under way, 23 of them phase 3. Alzheimer Disease · Canada.

Planned enrollment
216th of 281
50 · median 241
Started
2025
with 20 others
No phase
68 of 321
19 open now
Primary completion
2025-06
later than 9 of 80 live
Registered
287th of 321
by date
Lead sponsor
8 of 321
Centre for Addiction and Mental Health

Among the 321 studies in Alzheimer Disease with a site in Canada, this one is the 216th largest by planned enrollment of the 281 interventional ones that give a count, is one of 21 that started in 2025, is one of 68 with no phase, reaches primary completion later than 9 of the 80 other live ones, and was the 287th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

60 of the 321 studies in Alzheimer Disease with a site in Canada are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Alzheimer Disease with a site in Canada, or all of them as a file.
02

Study summary

Behavioural and psychological symptoms of dementia (BPSD), such as depression affect up to 90% patients with dementia. Non-pharmacological treatment of BPSD, can be difficult to access, require caregiver support, travel, and often have long waiting lists. Virtual reality (VR) is an innovative, portable, immersive, and accessible technology which can be used in-home. More information is required on the feasibility of using VR in-home with older adults with dementia.

Our study will offer a 4-week program of 15-minutes sessions, twice per week nature-based VR program for BPSD delivered in-home by virtual reality (VR). Additionally, caregivers will have the option of taking part in the study and provide feedback regarding the VR intervention. If successful, this project has the potential to prolong aging in place for individuals with BPSD, as BPSD is a significant factor in institutionalization.

Read the detailed description

The burden of dementia is rapidly growing, affecting nearly 50 million individuals globally and costing $818 billion dollars yearly. Alzheimer's disease (AD) is the most common form of dementia. AD includes changes in mood and behavior, referred to as the behavioral and psychological symptoms of dementia (BPSD). Depression is among the most common BPSD, impacting 50% of older adults with AD. Existing pharmacological treatment for depressive symptoms in AD (AD-D) lack evidence for efficacy and have many potential side effects (e.g. cognitive impairments, falls, mortality), Non-pharmacological interventions have been recommended but are associated with significant challenges such as travel, cost and the difficulty in accessing specialized therapists.

Virtual reality (VR), an immersive audiovisual technology, can address these challenges as it is an accessible and cost-effective intervention which can be delivered in a variety of settings. VR can easily be delivered in-home, and therefore address many of the limitations of traditionally delivered non-pharmacological interventions, such as accessibility, intervention non-adherence and difficulties with maintaining intervention frequency. Additional technology will be utilized to collect physiological data such as movement using the Fitbit Charge 6 and a Muse headband will measure electroencephalogram (EEG). Previous literature on VR based intervention for older adults is limited, with very few randomized control trials, rather it is primarily case studies, cross-sectional studies, and non-immersive VR. However, there are no studies assessing in-home VR for individuals with AD or for AD-D.

We propose a pilot randomized controlled trial (RCT) to assess nature-based VR intervention (N-VR) for AD-D. We will randomize (1:1) 50 participants with AD-D to N-VR vs. an active control intervention of various nature-based videos (N-CI). All participants will receive the intervention as 15-min sessions delivered twice a week, assessor-blinded, for 4 weeks. Assessments will be conducted at baseline, within 7 days of starting the intervention, at follow-up, within 7 days of completing the 4-week course, and after each 15-min session.

03

Conditions studied

  • Alzheimer Disease
  • Depression

Keywords

  • virtual reality
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of mild to early-moderate stage AD (including mixed dementia with AD) using the , 5th Ed. Criteria
  • Age of 50 years or older
  • Medical stability to participate in the trial
  • Patient Health Questionnaire score 5-14
  • Investigator judgement on whether the participant is comfortable with technology
  • Access to WiFi and a smart device for connecting on WebEx and downloading the Fitbit and Muse applications
  • Have someone available to be present during all sessions

Exclusion criteria

Exclusion Criteria:

  • Unstable medical or psychiatric condition, including substance use based on an investigator opinion
  • Visual or hearing impairments that would impair participation
  • Patient Health Questionnaire score 15-27 and/or score of 1 or 2 in section E question 1 of the Cornell Scale for Depression in Dementia
  • Any other reason, which will make the study participation intolerable for the participant in the opinion of the study investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.

    Other: nature-based virtual reality applications and videos

  • Active comparator
    Control Group

    Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).

    Other: nature-based videos

Interventions

  • Othernature-based virtual reality applications and videos

    Participants will receive nature-based applications available on the Oculus platform, as well as nature-based 360 videos with the same content as the control group however in a 360 format.

  • Othernature-based videos

    Participants will receive YouTube links to watch nature-based videos on a device (e.g., a tablet).

06

What researchers measure

Primary outcomes

  1. Tolerability of nature-based virtual reality

    Hypothesis 1a (Tolerability): Using the Simulator Sickness Questionnaire (SSQ) at the end of the last session, the mean SSQ score for N-VR group will be less than 10 (with 10 or more being the cut-off for clinically significant cybersickness)

    Time frame: 4 weeks

  2. Feasibility of nature-based virtual reality

    The number of sessions completed and major/minor technical issues during the session.

    Time frame: 4 weeks

  3. Acceptability of nature-based virtual reality

    The Personal Involvement Inventory (PII) score mean after the last N-VR completed session.

    Time frame: 4 weeks

Secondary outcomes

  1. Depression in AD-D

    The Cornell Scale for Depression in Dementia (CSDD) score improvement over 4 weeks for the N-VR versus control group.

    Time frame: 4 weeks

Other outcomes

  1. Caregiver participant exploratory outcome

    The experiences of AD-D participants' caregivers with the VR intervention, VR usability with AD-D, what they liked/had challenges with, and feedback for future VR use with this population (qualitative-focus group).

    Time frame: 4 weeks

  2. AD-D participant exploratory outcome - quality of life

    The preliminary efficacy of N-VR in improving quality of life in individuals with AD-D using the Quality of Life in Alzheimer's Disease (QOL-AD).

    Time frame: 4 weeks

  3. AD-D participant exploratory outcome - perceived stress

    The preliminary efficacy of N-VR in improving stress in individuals with AD-D using the Perceived Stress Scale (PSS) and data from the Fitbit Charge 6.

    Time frame: 4 weeks

  4. AD-D participant exploratory outcome - attention

    The preliminary efficacy of N-VR in improving attention in individuals with AD-D using the Montreal Cognitive Assessment (MoCA) attention task.

    Time frame: 4 weeks

  5. AD-D participant exploratory outcome - pleasure

    The preliminary efficacy of N-VR in improving pleasure in individuals with AD-D using the Snaith-Hamilton Pleasure Scale (SHAPS).

    Time frame: 4 weeks

  6. AD-D participant exploratory outcome - sleep

    The preliminary efficacy of N-VR in improving sleep in individuals with AD-D determined by the number of hours the participant slept, collected by the Fitbit Charge 6.

    Time frame: 4 weeks

  7. AD-D exploratory outcome - calmness

    The preliminary efficacy of N-VR in improving calmness in individuals with AD-D using data from the Muse headband.

    Time frame: 4 weeks

  8. AD-D exploratory outcome - loneliness

    The preliminary efficacy of N-VR in decreasing loneliness in individuals with AD-D using the UCLA loneliness scale.

    Time frame: 4 weeks

  9. AD-D exploratory outcome - nature relatedness

    The preliminary efficacy of N-VR in improving nature relatedness in individuals with AD-D using the Nature-Relatedness Scale short version (NR-6).

    Time frame: 4 weeks

  10. AD-D participants exploratory outcome - activity

    The preliminary efficacy of N-VR in increasing activity in individuals with AD-D, determined by baseline vs post-assessment average over 5 days using Fitbit.

    Time frame: 4 weeks

  11. AD-D participant exploratory outcome - presence

    The preliminary efficacy of N-VR in improving presence in individuals with AD-D using the Slater-Usoh-Steed Presence Questionnaire (SUS).

    Time frame: 4 weeks

  12. AD-D participant exploratory outcome - immersion

    The preliminary efficacy of N-VR in improving immersion using the Immersive Tendencies Questionnaire (ITQ).

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Centre for Addictions and Mental Health (CAMH)
    Toronto, Ontario L5V 2X3, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jun 2025, 5 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 5 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Dec 13, 2024
StartEst.
Jan 6, 2025
Primary completionEst.
Jun 11, 2025
CompletionEst.
Nov 11, 2025
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06732128
Collaborators
St. Mary's Research Center, Canada
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Jan 6, 2025 (estimated)
Primary completion
Jun 11, 2025 (estimated)
Completion
Nov 11, 2025 (estimated)
Last update
Dec 13, 2024

Study contacts

Ashnie Sukhu, BSc
Contact
ashnie.sukhu@camh.ca
(416) 535-8501 ext. 31923
HARMEHR SEKHON, PhD
principal investigator · CAMH and McGill/St. Mary's Research Centre
Eric Brown, MD
principal investigator · CAMH and UofT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion